Launch week offerEnds in00h00m00s

annual Promonthly Pro

LANA E. KANDALAFT

Associate Professor

University of Lausanne

Switzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

About

Dr. Lana E. Kandalaft is an Associate Professor at the University of Lausanne, Switzerland. Her research focuses on immunotherapy, particularly in the context of cancer therapies, including ovarian cancer and prostate cancer. Recent publications explore topics such as T cell reactivity, cancer vaccines, and the role of immune cell subsets in cancer progression.

Articles (17)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (16)

Laurent Derré

Head of the Urology Research Unit and Urology Biobank

Lausanne University Hospital

SWITZERLAND

LANA E. KANDALAFT

Research Interests

Make your next move.

Explore related searches

About

Articles (17)

Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer

CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers

Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity

TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs

A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer

Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development

Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma

Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation

Sensitive identification of neoantigens and cognate TCRs in human solid tumors

The current clinical landscape of personalized cancer vaccines

Polymer Nanoparticle‐Mediated Delivery of Oxidized Tumor Lysate‐Based Cancer Vaccines

Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

Reduction-Sensitive Protein Nanogels Enhance Uptake of Model and Tumor Lysate Antigens In Vitro by Mouse- and Human-Derived Dendritic Cells

TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation

Collaborators (16)

Laurent Derré

John Prior

George Coukos

Olivier Michielin

Alexandre Harari

Michel Cuendet

Nathalie Rufer

Beatrice Zitti

Sylvain Nguyen

Mikael J. Pittet

Beat Roth

Allon Klein

Michal Bassani-Sternberg

Spyridon Mastroyannis

Máté Kiss

Krisztian Homicsko

Make your next move.